Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

site-specific antibody-drug conjugates

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (2) Drug-Linker Conjugates for ADC (2) ADC Antibody (2) Amino Acid Derivatives (2) CD22 (1) PROTAC Linkers (1)
By Research Areas:	Cancer (7) Infection (1) Inflammation/Immunology (1)
Click Chemistry:	Azide (2)

Inhibitors & Agonists

Inhibitory Antibodies

Click Chemistry

Targets Recommended: Antibody-Drug Conjugates (ADCs) ADC Linker Target Protein Ligand-Linker Conjugates Peptide-Drug Conjugates (PDCs) PROTAC-Linker Conjugates for PAC Radionuclide-Drug Conjugates (RDCs) Drug-Linker Conjugates for ADC Antibody-Oligonucleotide Conjugates (AOCs) E3 Ligase Ligand-Linker Conjugates

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111434A

N6-[(2-Azidoethoxy)carbonyl]-L-lysine hydrochloride UAA crosslinker 1 hydrochloride	Amino Acid Derivatives	Cancer
N6-[(2-Azidoethoxy)carbonyl]-L-lysine hydrochloride (UAA crosslinker 1 hydrochloride) is a click chemistry-reactive amino acid derivative. N6-[(2-Azidoethoxy)carbonyl]-L-lysine hydrochloride mediates the generation of antibody-drug conjugates (ADCs). N6-[(2-Azidoethoxy)carbonyl]-L-lysine hydrochloride is used for site-specific incorporation into recombinant proteins, or for synthesizing chemical probes and tools for biological research .

HY-130426

Maleimido-tri(ethylene glycol)-propionic acid Mal-PEG3-acid	ADC Linker PROTAC Linkers	Cancer
Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors for site-specific cysteine mutant trastuzumab-A114C conjugation . Maleimido-tri(ethylene glycol)-propionic acid also can be used as a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

HY-P99238

Rolinsatamab	ADC Antibody	Inflammation/Immunology Cancer
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an **antibody-drug conjugate*, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific* drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .

HY-111434

N6-[(2-Azidoethoxy)carbonyl]-L-lysine UAA crosslinker 1	Amino Acid Derivatives	Cancer
N6-[(2-Azidoethoxy) carbonyl]-L-lysine (UAA crosslinker 1) is a click chemistry-reactive amino acid derivative. N6-[(2-Azidoethoxy) carbonyl]-L-lysine mediates the generation of antibody-drug conjugates (ADCs). N6-[(2-Azidoethoxy) carbonyl]-L-lysine is used for site-specific incorporation into recombinant proteins, or for synthesizing chemical probes and tools for biological research .

HY-177542

Emiltatug ledadotin Emi-Le; XMT-1660		Cancer
Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4-targeted antibody-drug conjugate (ADC). Emiltatug ledadotin consists of the tumor-specific anti-B7-H4 monoclonal antibody Emiltatug (HY-P990918) and the linker-payload system Ledadotin (HY-177541), with site-specific conjugation achieved via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used to study advanced solid tumors with B7-H4 overexpression, particularly breast cancer, ovarian cancer, and endometrial cancer .

HY-139957

Mal-amido-PEG8-Val-Ala-PAB-SG3200	Drug-Linker Conjugates for ADC	Others
Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a conjugate for antibody-drug conjugate (ADC) (extracted from patent WO2016166300A1) .

HY-P991906

TRPH-222 Antibody CD22-4AP antibody; CAT-02-106 antibody	ADC Antibody CD22	Cancer
TRPH-222 Antibody (CD22-4AP Antibody) is an anti-human CD22 antibody site-specifically modified at one site per heavy chain to express formylglycine (FG), allowing site-specific conjugation of a maytansinoid payload, a protease-insensitive spacer, and a functional group for coupling to an aldehyde on antibody FG residues. TRPH-222 Antibody can generate antibody drug conjugate (ADC) (TRPH-222) with an ADC payload and a linker. TRPH-222 Antibody can be used for the study of NHL (non-Hodgkin's lymphoma) .

HY-180467A

Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me sodium	ADC Linker	Cancer
Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me (Compound G12) sodium is a disaccharide linker. Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me sodium can be efficiently recognized by the endo-glycosidase Endo-S2 and can be directedly transferred to the conserved N-glycosylation site (Asn297 position) of the antibody's Fc domain through enzymatic catalytic reactions, thereby achieving site-specific modification of the antibody. Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me sodium can be used for for the synthesis of **antibody-conjugated drugs (ADCs**) .

HY-180563

ADC 38 drug linker	Drug-Linker Conjugates for ADC	Infection
ADC 38 drug linker is a drug linker coupling agent used for ADCs, consisting of a CD4 mimic and a linker. ADC 38 drug linker can be used to synthesize antibody-drug conjugates (ADCs), such as ADC 38 .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99238

Rolinsatamab	ADC Antibody	Inflammation/Immunology Cancer
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an **antibody-drug conjugate*, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific* drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .

HY-P991906

TRPH-222 Antibody CD22-4AP antibody; CAT-02-106 antibody	ADC Antibody CD22	Cancer
TRPH-222 Antibody (CD22-4AP Antibody) is an anti-human CD22 antibody site-specifically modified at one site per heavy chain to express formylglycine (FG), allowing site-specific conjugation of a maytansinoid payload, a protease-insensitive spacer, and a functional group for coupling to an aldehyde on antibody FG residues. TRPH-222 Antibody can generate antibody drug conjugate (ADC) (TRPH-222) with an ADC payload and a linker. TRPH-222 Antibody can be used for the study of NHL (non-Hodgkin's lymphoma) .

Cat. No.	Product Name		Classification

HY-111434A

N6-[(2-Azidoethoxy)carbonyl]-L-lysine hydrochloride UAA crosslinker 1 hydrochloride		Azide
N6-[(2-Azidoethoxy)carbonyl]-L-lysine hydrochloride (UAA crosslinker 1 hydrochloride) is a click chemistry-reactive amino acid derivative. N6-[(2-Azidoethoxy)carbonyl]-L-lysine hydrochloride mediates the generation of antibody-drug conjugates (ADCs). N6-[(2-Azidoethoxy)carbonyl]-L-lysine hydrochloride is used for site-specific incorporation into recombinant proteins, or for synthesizing chemical probes and tools for biological research .

HY-111434

N6-[(2-Azidoethoxy)carbonyl]-L-lysine UAA crosslinker 1		Azide
N6-[(2-Azidoethoxy) carbonyl]-L-lysine (UAA crosslinker 1) is a click chemistry-reactive amino acid derivative. N6-[(2-Azidoethoxy) carbonyl]-L-lysine mediates the generation of antibody-drug conjugates (ADCs). N6-[(2-Azidoethoxy) carbonyl]-L-lysine is used for site-specific incorporation into recombinant proteins, or for synthesizing chemical probes and tools for biological research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.